Xilio Therapeutics, Inc. (XLO)
Automate Your Wheel Strategy on XLO
With Tiblio's Option Bot, you can configure your own wheel strategy including XLO - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol XLO
- Rev/Share 0.1241
- Book/Share 0.1432
- PB 4.6433
- Debt/Equity 0.735
- CurrentRatio 1.9565
- ROIC -0.9932
- MktCap 34440389.0
- FreeCF/Share 0.2817
- PFCF 1.6366
- PE -1.2107
- Debt/Assets 0.0758
- DivYield 0
- ROE -1.9852
- Rating C
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 5
- P/B Score 1
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| No ratings available. | |||||||
News
Xilio Therapeutics Announces Pricing of $50.0 Million Public Offering
Published: June 02, 2025 by: GlobeNewsWire
Sentiment: Neutral
WALTHAM, Mass., June 02, 2025 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living with cancer, today announced the pricing of an underwritten public offering of pre-funded warrants to purchase 66,676,000 shares of common stock (the “pre-funded warrants”), accompanied by Series A warrants to purchase 66,676,000 shares of common stock (or, in certain circumstances, pre-funded warrants) (the “Series A warrants”), Series B warrants to purchase 66,676,000 shares of common stock (or, in certain circumstances, pre-funded warrants) (the “Series B warrants”) and Series C warrants to purchase 66,676,000 shares …
Read More
Xilio Therapeutics Announces Proposed Public Offering
Published: June 02, 2025 by: GlobeNewsWire
Sentiment: Neutral
WALTHAM, Mass., June 02, 2025 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living with cancer, today announced that it is commencing an underwritten public offering of pre-funded warrants to purchase shares of common stock accompanied by Series A warrants to purchase shares of common stock (or, in certain circumstances, pre-funded warrants), Series B warrants to purchase shares of common stock (or, in certain circumstances, pre-funded warrants) and Series C warrants to purchase shares of common stock (or, in certain circumstances, pre-funded warrants). All of the securities to …
Read More
Xilio Therapeutics Announces Pipeline and Business Updates and First Quarter 2025 Financial Results
Published: May 08, 2025 by: GlobeNewsWire
Sentiment: Neutral
Updated Phase 2 data to be presented at ASCO for vilastobart, a tumor-activated, Fc-enhanced, anti-CTLA-4, in combination with atezolizumab in patients with metastatic microsatellite stable colorectal cancer (MSS CRC) Advancing multiple masked T cell engager programs utilizing Xilio's novel ATACR and SEECR formats, with first development candidates anticipated in second half of 2025 WALTHAM, Mass., May 08, 2025 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living with cancer, today announced pipeline progress and business updates and reported financial results for the first quarter ended March 31, 2025.
Read More
Xilio Therapeutics, Inc. (XLO) Reports Q4 Loss, Lags Revenue Estimates
Published: March 11, 2025 by: Zacks Investment Research
Sentiment: Negative
Xilio Therapeutics, Inc. (XLO) came out with a quarterly loss of $0.20 per share versus the Zacks Consensus Estimate of a loss of $0.22. This compares to loss of $0.64 per share a year ago.
Read More
Xilio Therapeutics to Present at TD Cowen 45th Annual Health Care Conference
Published: February 24, 2025 by: GlobeNewsWire
Sentiment: Neutral
WALTHAM, Mass., Feb. 24, 2025 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living with cancer, today announced that René Russo, Pharm.D., president and chief executive officer, will participate in a fireside chat at the TD Cowen 45th Annual Health Care Conference on Monday, March 3, 2025 at 9:50 am EST.
Read More
Xilio Therapeutics Announces Multiple Masked T Cell Engager Programs
Published: February 12, 2025 by: GlobeNewsWire
Sentiment: Neutral
Also entered into collaboration and option agreement with AbbVie to develop novel tumor-activated immunotherapies, including masked T cell engagers, with $52.0 million in upfront payments
Read More
AbbVie and Xilio Therapeutics Announce Collaboration and Option Agreement to Develop Novel Tumor-Activated Immunotherapies
Published: February 12, 2025 by: GlobeNewsWire
Sentiment: Neutral
NORTH CHICAGO, Ill. and WALTHAM, Mass., Feb. 12, 2025 (GLOBE NEWSWIRE) -- AbbVie (NYSE: ABBV) and Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living with cancer, today announced a collaboration and option-to-license agreement to develop novel tumor-activated, antibody-based immunotherapies, including masked T-cell engagers, leveraging Xilio's proprietary technology.
Read More
AbbVie and Xilio Therapeutics Announce Collaboration and Option Agreement to Develop Novel Tumor-Activated Immunotherapies
Published: February 12, 2025 by: PRNewsWire
Sentiment: Neutral
Collaboration will combine AbbVie's oncology expertise and Xilio's proprietary tumor-activation technology to develop novel immunotherapies, including masked T-cell engagers Xilio to host investor conference call and webcast today at 8:30 am EST NORTH CHICAGO, Ill. and WALTHAM, Mass.
Read More
About Xilio Therapeutics, Inc. (XLO)
- IPO Date 2021-10-22
- Website https://www.xiliotx.com
- Industry Biotechnology
- CEO Dr. Rene Russo BCPS, Pharm.D.
- Employees 64